L
Lucía Martínez-Costa
Researcher at University of Valencia
Publications - 35
Citations - 641
Lucía Martínez-Costa is an academic researcher from University of Valencia. The author has contributed to research in topics: Uveitis & Medicine. The author has an hindex of 11, co-authored 29 publications receiving 481 citations.
Papers
More filters
Journal ArticleDOI
Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients
Vanesa Calvo-Río,Ricardo Blanco,Emma Beltrán,Juan Sánchez-Bursón,Marina Mesquida,Alfredo Adán,Maria Victoria Hernández,Marisa Hernandez Garfella,Elia Valls Pascual,Lucía Martínez-Costa,Agusti Sellas-Fernández,Miguel Cordero Coma,Manuel Díaz-Llopis,Roberto Gallego,David Salom,José Luis García Serrano,Norberto Ortego,José M. Herreras,Alejandro Fonollosa,Ángel García-Aparicio,O. Maíz,Ana Blanco,Ignacio García-De La Torre,Cruz Fernández-Espartero,Vega Jovani,Diana Peiteado-Lopez,Esperanza Pato,Juan Cruz,Carlos Marras Fernandez-Cid,Elena Aurrecoechea,M A García,M.A. Caracuel,Carlos Montilla,Antonio Atanes,Félix Francisco Hernandez,Santos Insua,Senén González-Suárez,Amalia Sánchez-Andrade,Fernando Gamero,L. Linares,Fredeswinda Romero-Bueno,A Javier García,Raquel Almodóvar,Enrique Minguez,Carmen Carrasco Cubero,Alejandro Olivé,J. Vazquez,Oscar Ruiz Moreno,Fernando Jiménez-Zorzo,Javier Manero,Santiago Muñoz Fernández,Javier Rueda-Gotor,Miguel A. González-Gay +52 more
TL;DR: Anti-TNF-α therapy is effective and relatively safe in refractory BD uveitis and the best-corrected visual acuity and the suppression load also showed significant improvement.
Journal ArticleDOI
Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
Belén Atienza-Mateo,Vanesa Calvo-Río,Emma Beltrán,Lucía Martínez-Costa,Elia Valls-Pascual,Marisa Hernández-Garfella,Antonio Atanes,Miguel Cordero-Coma,Joan M. Nolla,Carmen Carrasco-Cubero,Javier Loricera,María Carmen González-Vela,N. Vegas-Revenga,C. Fernández-Díaz,R. Demetrio-Pablo,L Domínguez-Casas,José Luis Martín-Varillas,Natalia Palmou-Fontana,José L. Hernández,Miguel A. González-Gay,Ricardo Blanco +20 more
TL;DR: TCZ yielded rapid and maintained improvement in all ocular parameters of the patients, with complete remission in eight of them, but this was not the case for the extraocular manifestations, since TCZ was only effective in three of them.
Journal ArticleDOI
Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.
N. Vegas-Revenga,Vanesa Calvo-Río,Marina Mesquida,Alfredo Adán,Maria Victoria Hernández,Emma Beltrán,Elia Valls Pascual,David Díaz-Valle,Gisela Díaz-Cordovés,Marisa Hernández-Garfella,Lucía Martínez-Costa,Inmaculada Calvo,Antonio Atanes,L. Linares,Consuelo Modesto,Carmen González-Vela,R. Demetrio-Pablo,Elena Aurrecoechea,Miguel Cordero,L Domínguez-Casas,Belén Atienza-Mateo,José Luis Martín-Varillas,Javier Loricera,Natalia Palmou-Fontana,José L. Hernández,Miguel A. González-Gay,Ricardo Blanco +26 more
TL;DR: Macular thickness is reduced following administration of tocilizumab (TCZ) in refractory uveitis-related CME, a statistically significant improvement in macular thickness compared to baseline.
Journal Article
Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review
Calvo-Río,de la Hera D,E. Beltrán-Catalán,Ricardo Blanco,Maria Victoria Hernández,Lucía Martínez-Costa,Javier Loricera,J. Cañal,J. Ventosa,Francisco Ortiz-Sanjuán,Trinitario Pina,María Carmen González-Vela,P. Rodriguez-Cundin,M. A. González-Gay +13 more
TL;DR: TCZ appears to be an effective and safe therapy for the management of patients with uveitis refractory to other biologic drugs.
Journal ArticleDOI
Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease
José Luis Martín-Varillas,Vanesa Calvo-Río,Emma Beltrán,Juan Sánchez-Bursón,Marina Mesquida,Alfredo Adán,Maria Victoria Hernández,Marisa Hernandez Garfella,Elia Valls Pascual,Lucía Martínez-Costa,Agusti Sellas-Fernández,Miguel Cordero-Coma,Manuel Díaz-Llopis,Roberto Gallego,David Salom,Norberto Ortego,José L. García-Serrano,José-Luis Callejas-Rubio,José M. Herreras,Ángel García-Aparicio,O. Maíz,Ana Blanco,Ignacio García-De La Torre,David Díaz-Valle,Esperanza Pato,Elena Aurrecoechea,M.A. Caracuel,Fernando Gamero,Enrique Minguez,Carmen Carrasco-Cubero,Alejandro Olivé,J. Vazquez,Oscar Ruiz-Moreno,Javier Manero,Santiago Muñoz-Fernández,Myriam Gandía Martinez,Esteban Rubio-Romero,F. Javier Toyos-Sáenz de Miera,Francisco Javier López Longo,Joan M. Nolla,Marcelino Revenga,Carmen González-Vela,Javier Loricera,Belén Atienza-Mateo,R. Demetrio-Pablo,José L. Hernández,Miguel A. González-Gay,Ricardo Blanco +47 more
TL;DR: ADA optimization in BD uveitis refractory to conventional therapy is effective, safe, and cost-effective, and the mean ADA treatment costs were lower in the optimized group than in the nonoptimized group.